Thus, our statistical power is limited in addressing this question, and we cannot yet distinguish whether the effect of the PCK1 locus is one of accelerated brain atrophy in the context of MS or whether PCK1 affects the maximal BPF attained in the course of brain development. This evidence concerns the gene PCK1 and myeloid sarcoma.